rosufy 10 mg tabletki powlekane
centrient pharmaceuticals netherlands b.v. - rosuvastatinum calicum - tabletki powlekane - 10 mg
rosufy 20 mg tabletki powlekane
centrient pharmaceuticals netherlands b.v. - rosuvastatinum calicum - tabletki powlekane - 20 mg
rosufy 40 mg tabletki powlekane
centrient pharmaceuticals netherlands b.v. - rosuvastatinum calicum - tabletki powlekane - 40 mg
exitel 230 mg + 20 mg tabletka
chanelle pharmaceuticals manufacturing ltd. - pyranteli embonas + praziquantelum - tabletka - 230 mg + 20 mg - kot
kalydeco
vertex pharmaceuticals (ireland) limited - iwakaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
dolenio 1178 mg tabletki powlekane
blue bio pharmaceuticals limited - glucosaminum - tabletki powlekane - 1178 mg
olanzapina stada 5 mg tabletki powlekane
stada arzneimittel ag - olanzapinum - tabletki powlekane - 5 mg
olanzapina stada 10 mg tabletki powlekane
stada arzneimittel ag - olanzapinum - tabletki powlekane - 10 mg
metotab 2,5 mg 2,5 mg tabletki
medac gesellschaft für klinische spezialpräparate mbh - methotrexatum - tabletki - 2,5 mg
metotab 7,5 mg 7,5 mg tabletki
medac gesellschaft für klinische spezialpräparate mbh - methotrexatum - tabletki - 7,5 mg